IDRA - Piper Jaffray presentation. CEO stated there will be 1 or 2 more indications announced early 2014 and an IND will be filed for IMO-9200... also said they will look to partner IMO-8400 for psoriasis in 2H 2014 but will retain all rights for orphans.